/
California Criminal Justice Reform: Recidivism Reduction Tr California Criminal Justice Reform: Recidivism Reduction Tr

California Criminal Justice Reform: Recidivism Reduction Tr - PowerPoint Presentation

celsa-spraggs
celsa-spraggs . @celsa-spraggs
Follow
390 views
Uploaded On 2017-12-08

California Criminal Justice Reform: Recidivism Reduction Tr - PPT Presentation

Psychotropic Medication in Treatment Courts Teresa Frausto MD Chief Medical Officer April 13 2016 No conflict of interest Disclaimer History of the mentally ill in corrections Review common diagnosis and medication treatments ID: 613627

anxiety medications treatment continued medications anxiety continued treatment anti disorders health symptoms antidepressant mood reactions community mental amp antidepressants

Share:

Link:

Embed:

Download Presentation from below link

Download Presentation The PPT/PDF document "California Criminal Justice Reform: Reci..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

Slide1

California Criminal Justice Reform: Recidivism Reduction Training

Psychotropic Medication in Treatment Courts

Teresa Frausto, M.D.

Chief Medical Officer

April 13, 2016Slide2

No conflict of interest.

DisclaimerSlide3

History of the mentally ill in corrections.

Review common diagnosis and medication treatments.Discuss treatment challenges.

Goals of PresentationSlide4

Origins of the Community Mental Health System

Deinstitutionalization of the severely mentally ill led to the trans institutionalization to the jails and prisons.

Funding from the cost savings achieved through the closures of the state hospitals to the community mental health system did not occur.

Unlike services to persons with developmental disabilities, the mental health system was never conceived as an “entitlement.”

Mental health services were to be provided “to the extent resources are available

.”Slide5

Although deinstitutionalization was well intentioned, the failure to provide treatment needs to the severely mentally ill has turned this policy into one of the greatest social disasters of the 20

th century.

Origins of the Community Mental Health SystemSlide6

Release of lower level offenders from the prisons back into the community.

Establishment of the Day Reporting Centers.Change in the population of the jails with more acute and chronic medical and mental health problems.

Assembly Bill 109Slide7

Most Commonly Used

Antipsychotics;Antidepressants;Antianxiety (Anxiolytic

);Mood Stabilizers;

 Psychostimulants; andOthers.

Psychotropic MedicationsSlide8

Indications

Psychotic symptomsSchizophrenia, Schizoaffective

Psychotic Symptoms

Other applicationsDelirium/dementia

Substance induced psychosis/agitationSevere aggression and violence behaviors

Severe Personality disorder

Antipsychotics - IndicationsSlide9

Psychotic Symptoms

Positive symptoms Hallucinations, delusion, disorganization, Agitation

Negative symptomsAlogia (speech), Avolition (drive), Anhedonia (pleasure), Apathy (flat affect)

Antipsychotics - Treatment of SymptomsSlide10

Atypical Antipsychotics

Clozapine (Clozaril)Risperidone (Risperdal) >>> (Risperdal Consta)

Olanzapine (Zyprexa, Zydis)>> (Zyprexa Relprev)*Quetiapine (Seroquel, Seroquel XR)

Ziprasidone (Geodon)Aripiprazole (Abilify)Paliperidone (Invega) >>> (Invega Sustenna)*

Iloperidone (Fanapt)*Asenapine (Saphris)*

Lurasidone (Latuda)*

Antipsychotic

- Medications

* Newer AP & Long Acting injectable APSlide11

Sedation,

weight gain and cognitive dulling Extrapyramidal symptoms (EPS)

Diabetes, Hypertension, increases in Cholesterol

Cardiac changes – for example arrhythmias

Antipsychotic - Adverse ReactionsSlide12

Antidepressant - Indications

Indicators

Depressive Disorders

Major Depression

Dysthymia, Depression not otherwise specified

Anxiety Disorders

Panic

disorders, Social

Phobia

Post-traumatic Stress Disorder (PTSD)

Other

applications

Eating disorders, Obsessive Compulsive Disorder

Premenstrual Dysphoric Disorder

Migraine, pain disorders, impulse control disordersSlide13

Depressive Symptoms

Pervasive depressed mood, Excessive guilt feelings, hopeless & helplessnessPsychomotor agitation or retardation

Severe sleep disturbancesAnhedonia, poor concentration

Preoccupation with physical healthDelusional / Suicide thoughts

Antidepressant - Treatment of SymptomsSlide14

Traditional Antidepressants*

Monoamineoxidase Inhibitors(MAOI)Phenelzine (Nardil)Tranylcypromine (Parnate)

Tricyclic Antidepressants (TCAs)Amitryptyline (Elavil)

Imipramine (Tofranil)Doxepin (Sinequan)

Clomipramine (Anafranil)**

Antidepressant - Medications

* Able to measure therapeutic drug level

**

Mainly for OCDSlide15

Traditional Antidepressants

(continued)Nortryptyline (Pamelor)Desipramine (Norpramin)

Protryptyline (Vivactil)Trimipramine (Surmontil)Amoxapine (Arsendin

)

Antidepressant – Medications (continued) Slide16

Newer Antidepressants

Serotinin reuptake inhibitors (SSRIs)Fluoxetine (Prozac)Paroxetine (Paxil, Paxil-CR)Sertraline (Zoloft)

Citalopram (Celexa)

Escitalopram (Lexapro)Fluvoxamine (Luvox / Luvox CR)*Vortioxetine (Brintellix)

Antidepressant – Medications

(continued)

* Primarily for OCDSlide17

Newer

Antidepressants (continued)Serotonin-Norepinephrine reuptake inhibitors

Venlafaxine (Effexor, Effexor XR)Duloxetine (Cymbalta)

Desvenlafaxine (Pristiq)Levomilnacipran (Fetzima)

Antidepressant – Medications

(continued) Slide18

Other Atypical Antidepressants

Mirtazapine (Remeron)Bupropion (Welbutrin, Welbutrin SR, Wellbutrin XL)Trazodone (Desyrel)

Vilazodone (Viibryd)Vortioxetine (Brintellix)

Antidepressant – Medications

(continued) Slide19

Orthostatic Hypotension

Dizziness, TachycardiaSedations, Weight gainHypertensive CrisisDry mouth, blurred vision,

constipationConduction disturbancesSeizures

Tremors, Ataxia, Delirium (toxic level)Erectile & ejaculatory dysfunctions

Antidepressant - Adverse ReactionsSlide20

Anxiety Disorders

Panic Disorder, Phobias including Social Anxiety DisorderGeneralized Anxiety Disorders, Acute Anxiety

Anxiety due to specific stressful life event(s)Other applications*Substance withdrawal

As Hypnotic / Sedative

Anti-Anxiety - Indications

*

Primarily for BenzodiazepinesSlide21

Anxiety Symptoms

Excessive worry & anxietyRestlessness or feeling on edge

Easily FatigabilityDifficulty concentrating

Irritability, Muscle tensionSleep disturbances

*Symptoms cause significant distress in daily social functioning

Neuropsychiatric basis of treatment

GABA receptors, Serotonin, Chloride ions

Anti-Anxiety - Treatment of SymptomsSlide22

SSRIs

First line treatment for Anxiety disordersFluoxetine (Prozac)Paroxetine (Paxil, Paxil-CR)

Sertraline (Zoloft)Citalopram (Celexa)

Escitalopram (Lexapro)Effexor, Effexor XR –FDA approved for Generalized Anxiety Disorder

Duloxetine (Cymbalta)

Anti-Anxiety

-

Medications Slide23

Benzodiazepines

Alprazolam (Xanax / Nirivum)Clonazepam (Klonopin)Diazepam (Valium)

Lorazepam (Ativum)

Non-Benzodiazepine Buspirone (BuSpar)

Hydroxyzine (Vistaril, Atarax)

Anti-Anxiety – Medications

(continued) Slide24

SSRIs

No immediate relieve of anxiety symptomsSafer long term side effect profileAnxiolytic Benzodiazepines

Most common

Sedation, Ataxia, Dizziness, Cognitive impairment, Anterograde amnesiaeRespiratory depression

Abuse, DependenceTolerance, Cross-tolerance, Withdrawal

Anti-Anxiety - Adverse ReactionsSlide25

Indications

Principle applicationsTreatment of Mania and Bipolar Disorders

Mood Disorders including Schizoaffective Disorder

Cyclothymia, Unipolar Depressions

Other applicationsImpulse Control Disorders

Severe Personality Disorder

Neuropsychiatric basis of treatment

Second messenger system (Inositol, Arachidonic Acid, Phospholipase-A2)

Mood Stabilizers - IndicationsSlide26

Mood stabilizers

Standard mood stabilizersLithium (Eskalith, Eskalith CR, Lithonate)

Valproate/ Divalproex (Depakene, Depakote)Carbamazepine (Tegretol)

Newer mood stabilizersLamotrigine (Lamictal)

Topiramate (Topamax)Oxcarbazepine (Trileptal)

Mood Stabilizers - MedicationsSlide27

Lithium

Most commonGI side effects ~ nausea and vomiting, Fine tremor, ‘Fuzzy feeling’Less common

Renal…Polyuria, polydipsia, Diabetes Insipidus

Thyroid…HypothyroidismDermatological…Rash & Acne

Neurological…muscle weakness, slurred speech (transient)Cardiac…EKG changes, Edema

Hematological…Benign Leukocytosis

Mood Stabilizers - Adverse ReactionsSlide28

Lithium toxicity

SymptomsNausea, Vomiting, Diarrhea, Coarse tremor, Ataxia, Headache, Slurred speech, Confusion & Cardiac arrhythmia may occur

CausesReduced fluid intake, Increased fluid & electrolytes loss (Excessive sweating, Diarrhea), Overdose

Drug interaction (Increased level by Diuretics, Non Steroidal Anti Inflammatory)

Adverse Drug Reactions

(continued)Slide29

Neurotransmitter

related reactions*Anti-cholinergic reactionsDry mouth, Constipation, Urinary retention, Blurred visionAnti-alpha adrenagic reactions

Orthostatic hypotension, Sedation, Techycardia

Anti-histamine reactionsSedation, fatigue, Weight gain*, Hyperglycemia*

Anti-dopamine reactionsParkinson like symptoms (masked faces, tremors, dystonia, shuffling gait)

Hyper Prolactinemia (Galactorrhea)

Akathisia

Miscellaneous

Hyper/hypothermia, photosensitivity, lower seizure threshold, rash, EKG changes (QT interval), Agranulocytosis

Neurotransmitter Related

R

eactions

*Anti-5HT1C

~

new warning for all Antipsychotic medicationsSlide30

How to get a mentally ill patient to:

Take their medications?Stay on their medications?

Treatment ChallengesSlide31

What about forced medications?

Treatment Challenges (continued) Slide32

When do you know the patient is stabilized on medications?

Treatment Challenges (continued) Slide33

Development of a Release Team to ensure a warm hand off of patients to community providers upon

release. Increase in patients receiving follow up mental health and substance use services in the community after release.

Community Reentry Slide34

Thank you!

Teresa Frausto, M.D.

Chief Medical Officer

County of San Bernardino Department of Behavioral Health